Searchable abstracts of presentations at key conferences in endocrinology

ea0020oc1.3 | Endocrine Tumours | ECE2009

131I-Iodometomidate radiotherapy for metastatic adrenocortical carcinoma: first clinical experience

Hahner Stefanie , Kreissl Michael , Fassnacht Martin , Johanssen Sarah , Haenscheid Heribert , Reiners Christoph , Allolio Bruno , Schirbel Andreas

Subject: Treatment options for adrenocortical carcinoma (ACC) are still unsatisfactory. We could recently demonstrate that several patients with ACC exhibit a high and specific uptake of 123I-Iodometomidate (123I-IMTO). Therefore, we investigated if 131I-IMTO holds potential for radiotherapy in ACC.Methods: Dosimetry with 40 MBq I-131-IMTO was performed over 5 days in 7 patients and calculated activities were administered on a compassionate use basis in ...

ea0014s8.4 | Advances in adrenal hypersecretory disorders | ECE2007

Adrenocortical carcinoma: current and future therapeutic options

Fassnacht Martin , Hahner Stefanie , Johanssen Sarah , Koschker Ann-Cathrin , Quinkler Marcus , Allolio Bruno

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with incompletely understood pathogenesis and poor prognosis. Recent data from the German ACC Registry (n=377) demonstrate an overall 5-year survival of 46%. Survival is clearly stage-dependent (P<0.01) with a 5-year survival of 85% in stage 1, 56% in stage 2, 42% in stage 3, and 16% in stage 4, respectively.In stages I –III open surgery by an expert surgeon aimi...

ea0020oc1.2 | Endocrine Tumours | ECE2009

Long-term outcome of laparoscopic versus open adrenalectomy for adrenocortical carcinoma

Fassnacht Martin , Brix David , Fenske Wiebke , Langer Peter , Nies Christoph , Agha Ayman , Beuschlein Felix , Johanssen Sarah , Riedmiller Hubertus , Allolio Bruno

Introduction: Surgery is the established first line treatment in adrenocortical carcinoma (ACC). For benign adrenal tumours, laparoscopic adrenalectomy (LA) has become the treatment of choice. However, the role of LA in ACC remains highly controversial. Data from the German ACC Registry were used to evaluate the technical feasibility of LA in ACC and to compare the long-term outcome after LA with the results of open adrenalectomy (OA).Methods: Out of 521...

ea0016p320 | Endocrine tumours | ECE2008

Mitotane induces a concentration-dependent impairment of platelet aggregation in patients with adrenocortical carcinoma

Hahner Stefanie , Eigenthaler Martin , Savvoukidis Theodoros , Johanssen Sarah , Wortmann Sebastian , Koschker Ann-Cathrin , Allolio Bruno , Fassnacht Martin

Standard treatment of adrenocortical carcinoma (ACC) comprises adrenolytic therapy with mitotane. Prolongation of bleeding time has previously been observed based on a series of 7 patients (Haak et al. 1991). As patients with ACC frequently undergo surgery for local recurrence or metastases, we have studied the effect of mitotane on coagulation in 44 patients with ACC before and/or during treatment with mitotane (total sample size n=62).Pla...

ea0022p23 | Adrenal | ECE2010

Sunitinib decreases adrenocortical cancer cell proliferation and specifically inhibits adrenal steroidogenesis

Reuss Miriam , Kroiss Matthias , Johanssen Sarah , Beyer Melanie , Zink Martina , Hartmann Michaela , Dhir Vivek , Wudy Stefan , Arlt Wiebke , Sbiera Silviu , Allolio Bruno , Fassnacht Martin

Background: The multi-tyrosine kinase inhibitor sunitinib is approved for advanced renal cell carcinoma and gastrointestinal stroma tumors. It targets both tumor vessels and malignant cells. Animal experiments have pointed to a direct adrenotoxic effect of the drug.Aims: We hypothesized that sunitinib may inhibit proliferation of adrenocortical cancer (ACC) cells and influence adrenal steroid hormone synthesis.Results: Sunitinib re...

ea0020p194 | Endocrine tumours and neoplasia | ECE2009

Impact of surgery on clinical outcome in patients with recurrence of adrenocortical carcinoma

Erdogan Ilknur , Hahner Stefanie , Johanssen Sarah , Fenske Wiebke , Quinkler Marcus , Willenberg Holger S , Beuschlein Felix , Brix David , Allolio Bruno , Fassnacht Martin

Introduction: The role of surgery for recurrent ACC is not well defined. Therefore, we used the German ACC Registry to evaluate treatment modalities after first recurrence in patients amenable to surgery.Methods: Patients with recurrence after radical resection and follow-up data were included. Patients with extensive metastasized disease (>2 tumoral organs, peritoneal carcinomatosis) were excluded. Progression-free and overall survival (PFS/OS) were...

ea0016s30.3 | Clinical highlights | ECE2008

[123I]Iodometomidate as a radiotracer for diagnosis of adrenal tumours and adrenocortical carcinoma

Hahner Stefanie , Schirbel Andreas , Kreissl Michael , Fassnacht Martin , Johanssen Sarah , Beuschlein Felix , Quinkler Marcus , Reincke Martin , Stuermer Andrea , Reiners Christoph , Allolio Bruno

Subject: Adrenal tumours (AT) are often detected incidentally and represent a variety of differential diagnoses with variable therapeutic consequences. We have recently developed [123I]Iodometomidate ([123I]IMTO), that specifically binds to adrenal CYP11B enzymes as a SPECT tracer for adrenal scintigraphy. This radiotracer is now evaluated in patients with adrenal tumours in an ongoing clinical trial. The study was approved by the ethical committee and pa...

ea0014p145 | (1) | ECE2007

Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma – results of pre-clinical studies

Fassnacht Martin , Hahner Stefanie , Heinrich Barbara , Adam Patrick , Johanssen Sarah , Quinkler Marcus , Koschker Ann-Cathrin , Stroebel Philipp , Marx Alexander , Allolio Bruno

Objectives: Adrenocortical carcinoma (ACC) is a rare malignancy with incompletely understood pathogenesis and poor prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been demonstrated in several tumors and is partly associated with a more aggressive phenotype and a worse prognosis. In addition, targeting the EGFR tyrosine kinase represents a successful new therapeutic strategy, e.g. in non-small cell lung cancer. Therefore, we investigated the role of EGF...

ea0016p333 | Endocrine tumours | ECE2008

Deficits in the clinical management of patients with adrenocortical carcinoma in Germany

Johanssen Sarah , Koschker Ann-Cathrin , Hahner Stefanie , Quinkler Marcus , Saeger Wolfgang , Morcos Michael , Willenberg Holger , Langer Peter , Klose Silke , Reisch Nicole , Beuschlein Felix , Brauckhoff Michael , Fottner Christian , Wortmann Sebastian , Oelkers Wolfgang , Maeder Uwe , Fassnacht Martin , Allolio Bruno

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Accordingly, in many cases, the attending doctors have no previous experience with the disease. The aim of our study was to evaluate the quality of care in a large number of patients with ACC in Germany. Data from 263 adult patients of the German ACC registry were analyzed with regard to the following parameters: time to diagnosis, hormonal assessment, imaging, histopathological documentation, follow-up. The...

ea0016p312 | Endocrine tumours | ECE2008

Prognostic factors in localized adrenocortical carcinoma (ACC) after complete resection

Obracay Jens , Fassnacht Martin , Saeger Wolfgang , Johanssen Sarah , Marcus Quinkler , Linden Tobias , Ann-Kathrin Koschker , Sebastian Wortmann , Morcos Michael , Willenberg Holger , Langer Peter , Behrend Matthias , Klose Silke , Reisch Nicole , Brauckhoff Michael , Petersenn Stephan , Bucsky Peter , Oelkers Wolfgang , Maeder Uwe , Hahner Stefanie , Allolio Bruno

Even after complete resection, patients with ACC have a high risk of relapse, and adjuvant treatment with mitotane is frequently recommended. Although mitotane has significant efficacy in this setting, it is associated with a wide range of side effects. As survival is highly variable, prognostic factors are of great interest to better guide adjuvant therapy after radical resection.We analyzed clinical and histopathological data of patients without distan...